Movement Disorders

Most people with Parkinson Disease develop cognitive impairment at some point. But this study provides evidence for sex differences in progression to cognitive impairment and dementia.

The FDA had accepted a new drug application for the inhaled levodopa therapy for the treatment of OFF period symptoms in patients with Parkinson disease who are taking a carbidopa/levodopa regimen.

Lower serum caffeine levels may be of diagnostic significance in early Parkinson disease, consistent with epidemiologic data that support the neuro-protective properties of caffeine.

The once-daily therapy will be available in 3 doses—129 mg, 193 mg, and 258 mg—giving patients flexibility in regimen setting among the options.

The encephalitis lethargica epidemic of 1916-1930 is estimated to have affected at least half a million of people in Europe and still remains a mystery.

Progressive supranuclear palsy (PSP), initially called Steele-Richardson-Olszewski syndrome, is a sporadic neurodegenerative disease.

A new study has found a link between Parkinson Disease (PD) and irritable bowel syndrome (IBS), and suggests that changes in the gut microbiome may be involved.

An incident, population-based prospective cohort study examined weight changes over time in patients with Parkinson disease.

Findings from a study in Neurology suggest that caffeine may be a biomarker for PD, which could represent a breakthrough for diagnosing PD using a simple blood test.

Sodium oxybate, a drug used to treat narcolepsy, may improve excessive daytime sleep and sleep disturbances in patients with Parkinson disease.

These technologies show promise in predicting dementia years before clinical symptoms develop; diagnosing concussion and other brain injuries; and more.

There has been long-running controversy regarding the association between statins and PD risk. Two studies with conflicting results are examined here.

Tools to help users monitor and detect tinnitus, control post-stroke symptoms, improve seizure monitoring, and more.

A new study found that the diabetes drug exenatide is associated with improved and sustained off-medication motor symptoms in PD, representing a major new avenue for treating the disorder.

Despite optimism, telemedicine has been only slowly adopted as a means of health care delivery. But things are changing. Have you considered adopting telemedicine in your clinic practice?

A study that compared motor and nonmotor outcomes of DBS for Parkinson disease may show promise for patients' quality of life.

Is caffeine consumption associated with risk for Parkinson disease? Is there a short-term benefit to caffeine that is sustainable over the long term? These questions and more in this quiz.

Delirium, psychosis, impulse control disorders: these are among the psychiatric problems associated with dopaminergic medications that control PD motor symptoms. Take the quiz.

An emphasis on importance of taking a detailed history and careful neurologic examination focused on the vestibular system.

While it is premature to conclude that changes in intestinal microbes influence the genesis or progression of PD, preliminary evidence indicates that they may be associated with inflammation in the intestinal wall.

This article provides some straightforward nutritional recommendations that neurologists can share with their patients.

Exenatide, a GLP-1 agonist, has been shown to protect neurons. The authors of two small studies of this agent's effects on motor function in Parkinson disease discuss the evidence here.

How common is psychosis in PD? Implications? Risk factors? Insights here, and measures that may help.

OI may serve for research purposes as a simple and inexpensive indicator of evolving AD pathology. Details here.